What is Yervoy's Price Reduction?
Yervoy (ipilimumab), Bristol Myers Squibb's immunotherapy for melanoma and other cancers, had its U.S. list price reduced by 30% in March 2020 from $158,000 to about $110,000 per standard 4-infusion course. This cut aimed to improve access amid pricing scrutiny.[1]
When Does the Price Reduction Expire?
The reduction has no fixed expiration date. Bristol Myers Squibb announced it as permanent, with no announced end or reversal as of 2024. Pricing remains at the lowered level, subject to annual adjustments via WAC (wholesale acquisition cost) updates.[1][2]
Why Did Bristol Myers Make This Cut?
Facing political pressure on drug prices and competition from checkpoint inhibitors like Keytruda, the company cut prices to maintain market share. It followed similar moves by competitors and aligned with Trump-era executive orders on affordability.[1]
How Has Yervoy's Price Changed Since?
Post-reduction, net prices (after discounts) fell further due to rebates and PBM negotiations. 2023 WAC for a full course hovered around $115,000-$120,000, down from pre-cut peaks, but patient out-of-pocket costs vary by insurance.[2][3]
What Happens If Prices Rise Again?
No plans exist for reversal, but inflation adjustments or supply shifts could nudge WAC up 5-10% yearly. Biosimilar entry post-patent expiry (around 2028-2030) would likely drive sharper drops.[4]
Yervoy Patent Timeline
Key U.S. patents on ipilimumab expire between 2027 (formulation) and 2031 (methods of use), per DrugPatentWatch. Challenges from Amgen and others could accelerate generic/biosimilar entry.[4]
[1] Bristol Myers Squibb press release, March 2020.
[2] IQVIA National Sales Perspectives, 2023.
[3] CMS Medicare Drug Spending Dashboard, 2024.
[4] DrugPatentWatch.com